Grace Therapeutics, Inc., a prominent late-stage biopharmaceutical company, has officially released its fiscal year-end financial results for 2026, marking significant progress in its clinical developments and corporate milestones. The Princeton, New Jersey-based company, listed on NASDAQ under the ticker symbol GRCE, focuses on advancing GTx-104, an innovative injectable formulation of nimodipine designed for intravenous infusion aimed at treating patients with aneurysmal subarachnoid hemorrhage (aSAH).
The financial disclosure coincides with the company’s announcement of a scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) to discuss the potential resubmission of the New Drug Application (NDA) for GTx-104. This follows the FDA’s issuance of a Complete Response Letter (CRL) in April 2026, which has set the stage for critical discussions aimed at addressing the FDA’s feedback and moving forward towards potential approval.
Prashant Kohli, CEO of Grace Therapeutics, expressed optimism about the company’s trajectory, especially in light of the recent regulatory challenges. “Following the FDA’s CRL earlier this year, our team has been intensely focused on clarifying and resolving the issues raised. We are eager to engage with the FDA to ensure our resubmission is robust and meets their criteria,” Kohli stated. The successful approval of GTx-104 would introduce the first significant advancement in the treatment of aSAH in over four decades, marking a milestone in medical care for this condition.
Grace Therapeutics has been proactive in presenting the Phase 3 STRIVE-ON safety trial data of GTx-104 at various medical conferences, showcasing the drug’s safety and efficacy profile. These presentations have been well-received by the medical community, providing valuable insights into the potential benefits of GTx-104 for aSAH patients.
In addition to its clinical development updates, Grace Therapeutics also highlighted its disciplined pre-commercial planning activities. The company is preparing for the possible market introduction of GTx-104, aligning its strategies to ensure a smooth transition from clinical to commercial stages upon potential FDA approval.
The company’s financial health remains robust as evidenced by the fiscal 2026 results. Grace Therapeutics reported a solid financial position, with sufficient capital to support its ongoing clinical trials and operational activities. This financial stability is crucial as the company navigates the complex regulatory environment and moves towards commercialization of its lead product.
Looking ahead, Grace Therapeutics plans to continue its engagement with healthcare professionals and regulatory bodies to ensure that GTx-104 reaches patients in need as swiftly as possible. The company’s leadership is confident in the strategic direction and the potential of GTx-104 to significantly impact the treatment landscape for aSAH.
The broader implications of GTx-104’s development are profound, potentially setting new standards in the care and outcomes of aSAH patients. Grace Therapeutics is at the forefront of this transformative phase in medical treatment, driven by scientific innovation and a deep commitment to patient care.
Strategic FDA Engagements
Type A Meeting and NDA Resubmission
The upcoming Type A meeting with the FDA is a critical step for Grace Therapeutics in addressing the concerns highlighted in the CRL. This meeting is expected to clarify the path forward for the NDA resubmission of GTx-104, focusing on the chemistry, manufacturing, and controls (CMC) issues that were previously identified.
Corporate and Financial Highlights
Fiscal Year 2026 Overview
The fiscal year 2026 has been pivotal for Grace Therapeutics with significant advancements in both the clinical and operational realms. The financial results revealed a strong capital foundation, supporting the company’s ambitious goals for GTx-104 and its long-term corporate health.
Clinical Trials and Medical Community Engagement
Phase 3 STRIVE-ON Safety Trial
The STRIVE-ON trial results have played a crucial role in validating the safety and efficacy of GTx-104. By presenting these findings at multiple key medical conferences, Grace Therapeutics has effectively engaged the medical community and garnered support for its innovative treatment approach.
Key People & Organizations
Prashant Kohli, the CEO of Grace Therapeutics, has been instrumental in navigating the company through recent regulatory challenges and steering the development of GTx-104. His leadership is pivotal as the company approaches potential FDA approval and prepares for the commercial launch of its flagship product.